Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 13
States / cities: Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more

Conditions: Healthy
Interventions: Fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: mazindol; Drug
Lead sponsor: NLS Pharmaceutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Newport Beach, California • Jacksonville, Florida • Marshfield, Massachusetts + 4 more

Conditions: Breast Cancer, Metastatic Cancer
Interventions: adenovirus-mediated human interleukin-12; Biological
Lead sponsor: Max Sung; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Ond-PR1, Ond-PR1 + MPh-IR, Ond-PR2, Ond-PR2 +_ MPh-IR; Drug
Lead sponsor: Tong Lee; Other
Eligibility: 18 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Periodontitis, Periodontal Diseases
Interventions: Scaling and root planing, Metronidazole, Amoxicillin, Doxycycline; Procedure · Drug
Lead sponsor: The Forsyth Institute; Other
Eligibility: 20 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Acute Myelogenous Leukemia (AML)
Interventions: Eltrombopag; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 60 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV
Interventions: Atazanavir (current formulation), Atazanavir, powder for oral use 1 (POU1), Atazanavir (POU2); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 332
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more

Conditions: Healthy Participants
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Menopause
Interventions: ERr 731 - Micro-coated, ERr 731 - Enteric coated; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 35 Years to 64 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Gig Harbor, Washington

Conditions: Hypertension
Interventions: COREG CR and lisinopril (FDC); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: PF-07976016 Formulation A, PF-07976016 Formulation B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: topiramate; Drug
Lead sponsor: Torrent Pharmaceuticals Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 1,950 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 35
States / cities: Birmingham, Alabama • Harrisburg, Arkansas • Downey, California + 28 more

Conditions: Restless Legs Syndrome
Interventions: Ropinirole Immediate Release; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Macon, Georgia • Chicago, Illinois + 4 more

Conditions: Caries
Interventions: 0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control); Drug
Lead sponsor: Domenick Zero; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Varicella, Rubella, Mumps, Measles
Interventions: Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 14 Months
Enrollment: 1,851 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 141
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more

Conditions: Immune System and Related Disorders, Immune System Diseases
Interventions: Cannabidiol (CBD); Dietary Supplement
Lead sponsor: NextEvo Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: PF-05221304 Formulation A, PF-05221304 Formulation B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: MK-0616A, Enlicitide, Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions: alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more

Conditions: Coronary Restenosis
Interventions: TAXUS Express2, Brachytherapy (beta source); Device · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 40
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 35 more

Search by objective public record fields.

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver

Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation

Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers

Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

ERr 731® Formulation Evaluation

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Study of Cannabidiol (CBD) in Healthy Volunteers

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis